AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
15 Jul 2024 07:00 AM
RNS
Acquisition of Amolyt Pharma completed
01 Jul 2024 03:00 PM
RNS
Total Voting Rights
01 Jul 2024 07:00 AM
RNS
Lynparza & Imfinzi positive CHMP in endometrial
25 Jun 2024 07:05 AM
RNS
Update on Imfinzi ADJUVANT BR.31 trial
25 Jun 2024 07:00 AM
RNS
Imfinzi improved EFS and OS in bladder cancer
18 Jun 2024 07:00 AM
RNS
Update on CAPItello-290 Phase III trial
17 Jun 2024 07:00 AM
RNS
Imfinzi approved in the US for endometrial cancer
12 Jun 2024 03:00 PM
RNS
Director/PDMR Shareholding
05 Jun 2024 07:00 AM
RNS
Acquisition of Fusion completed
03 Jun 2024 03:05 PM
RNS
Block listing Interim Review
03 Jun 2024 03:00 PM
RNS
Total Voting Rights
03 Jun 2024 07:00 AM
RNS
Tagrisso plus chemo recommended for approval in EU
28 May 2024 07:00 AM
RNS
Dato-DXd improved OS in nonsquamous lung cancer
21 May 2024 07:00 AM
RNS
AstraZeneca to deliver $80bn revenue by 2030
20 May 2024 07:00 AM
RNS
AstraZeneca to manufacture ADCs in Singapore
16 May 2024 07:00 AM
RNS
SUPERNOVA Trial Met COVID-19 prevention endpoint
15 May 2024 03:00 PM
RNS
Director/PDMR Shareholding
07 May 2024 07:00 AM
RNS
AstraZeneca completes Cellectis equity investment
02 May 2024 07:00 AM
RNS
Calquence combination improved PFS in 1L MCL
01 May 2024 03:00 PM
RNS
Total Voting Rights
29 Apr 2024 07:05 AM
RNS
Truqap recommended for EU breast cancer approval
29 Apr 2024 07:00 AM
RNS
Enhertu improved PFS in HER2-low and ultralow
25 Apr 2024 07:00 AM
RNS
1st Quarter Results
11 Apr 2024 05:30 PM
RNS
Result of AGM
11 Apr 2024 07:00 AM
RNS
AstraZeneca increases 2024 dividend by 7%
08 Apr 2024 07:00 AM
RNS
Enhertu approved in US for HER2+ solid tumours
05 Apr 2024 07:00 AM
RNS
Imfinzi improved OS & PFS in limited-stage SCLC
02 Apr 2024 03:00 PM
RNS
Total Voting Rights
02 Apr 2024 07:05 AM
RNS
Voydeya approved in US
02 Apr 2024 07:00 AM
RNS
FDA accepts Dato-DXd BLA for breast cancer
25 Mar 2024 07:00 AM
RNS
Ultomiris approved in the US for NMOSD
19 Mar 2024 07:00 AM
RNS
AstraZeneca to acquire Fusion
14 Mar 2024 07:00 AM
RNS
AstraZeneca to acquire Amolyt
12 Mar 2024 11:00 AM
RNS
Director/PDMR Shareholding
07 Mar 2024 11:00 AM
RNS
Notice of AGM
06 Mar 2024 03:05 PM
RNS
Director/PDMR Shareholding
06 Mar 2024 03:00 PM
RNS
Director/PDMR Shareholding
04 Mar 2024 07:00 AM
RNS
EMA validates Dato-DXd MAAs for NSQ NSCLC and BC
01 Mar 2024 03:00 PM
RNS
Total Voting Rights
26 Feb 2024 07:00 AM
RNS
Voydeya recommended for EU approval
22 Feb 2024 01:15 PM
RNS
Acquisition of Gracell completed
22 Feb 2024 11:00 AM
RNS
Director/PDMR Shareholding
22 Feb 2024 07:00 AM
RNS
AstraZeneca prices a $5bn bond offering
21 Feb 2024 07:00 AM
RNS
Filing of Form 20-F with SEC
20 Feb 2024 11:00 AM
RNS
Annual Financial Report
19 Feb 2024 03:00 PM
RNS
AstraZeneca completes acquisition of Icosavax
19 Feb 2024 07:10 AM
RNS
Tagrisso plus chemo approved in US for lung cancer
19 Feb 2024 07:05 AM
RNS
FDA accepts Dato-DXd BLA for nonsquamous NSCLC
19 Feb 2024 07:00 AM
RNS
Tagrisso improved PFS in Stage III lung cancer
08 Feb 2024 07:00 AM
RNS
Final Results
AstraZeneca PLC, known as AZN on the London Stock Exchange (LSE), is an Anglo-Swedish multinational pharmaceutical and biotechnology company. Founded on April 6, 1999, AstraZeneca was formed through the merger of the Swedish Astra AB and the British Zeneca Group. The company's roots trace back to 1913, when Astra AB was established by a group of doctors and apothecaries in Södertälje, Sweden. Throughout the twentieth century, AstraZeneca grew into one of the largest pharmaceutical companies in the world. It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014). Today, AstraZeneca operates in over 100 countries and employs around 83,000 people. As a member of the LSEG, AZN continues to shape the global healthcare landscape. The company is committed to defeating diseases that impact people's health.
UK 100

Latest directors dealings